XML 32 R21.htm IDEA: XBRL DOCUMENT
v3.20.2

Operating Segments | 9 Months Ended
--- | ---
Sep. 30, 2020
Segment Reporting [Abstract] |
Operating Segments |
12. | Operating Segments
In accordance with ASC 280, “Segment Reporting”, the Company defines an operating segment as a business activity: (1) from which we may earn revenue and incur expenses; (2) whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance; and (3) for which discrete financial information is available. Our reporting segments are defined as below: TREATMENT SEGMENT, which includes:
| ● | nuclear, low-level radioactive, mixed waste (containing both hazardous and low-level radioactive constituents), hazardous and non-hazardous waste treatment, processing and disposal services primarily through three uniquely licensed and permitted treatment and storage facilities; and
| ● | R&D activities to identify, develop and implement innovative waste processing techniques for problematic waste streams.
SERVICES SEGMENT, which includes:
| ● | Technical services, which include:
| ○ | professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering;
| ○ | integrated Occupational Safety and Health services including IH assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and OSHA citation assistance;
| ○ | global technical services providing consulting, engineering, project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers; and
| ○ | on-site waste management services to commercial and governmental customers.
| ● | Nuclear services, which include:
| ○ | technology-based services including engineering, decontamination and decommissioning (“D&D”), specialty services and construction, logistics, transportation, processing and disposal;
| ○ | remediation of nuclear licensed and federal facilities and the remediation cleanup of nuclear legacy sites. Such services capability includes: project investigation; radiological engineering; partial and total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; logistics; transportation; and emergency response; and
| ● | A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) health physics, IH and customized NIOSH instrumentation.
| ● | A company owned gamma spectroscopy laboratory for the analysis of oil and gas industry solids and liquids.
MEDICAL SEGMENT, which includes: R&D of the Company’s medical isotope production technology by our majority-owned Polish subsidiary, Perma-Fix of Medical or the Medical Segment. The Medical Segment has not generated any revenues and all costs incurred are reflected within R&D in the accompanying consolidated financial statements. As previously disclosed, the Medical Segment has substantially reduced its R&D costs and activities due to the need for capital to fund these activities. The Company anticipates that the Medical Segment will not resume full R&D activities until the necessary capital is obtained through its own credit facility or additional equity raise, or obtains partners willing to provide funding for its R&D. Our reporting segments exclude our corporate headquarters and our discontinued operations (see “Note 11 – Discontinued Operations”) which do not generate revenues. The table below presents certain financial information of our operating segments for the three and nine months ended September 30, 2020 and 2019 (in thousands). Segment Reporting for the Quarter Ended September 30, 2020
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 7,066 |  |  | $ | 23,106 |  |  |  | — |  |  | $ | 30,172 |  |  | $ | — |  |  | $ | 30,172 |
Intercompany revenues |  |  | 226 |  |  |  | 6 |  |  |  | — |  |  |  | 232 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 1,094 |  |  |  | 3,656 |  |  |  | — |  |  |  | 4,750 |  |  |  | — |  |  |  | 4,750 |
Research and development |  |  | 49 |  |  |  | 7 |  |  |  | 81 |  |  |  | 137 |  |  |  | 20 |  |  |  | 157 |
Interest income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 28 |  |  |  | 28 |
Interest expense |  |  | (34 | ) |  |  | (3 | ) |  |  | — |  |  |  | (37 | ) |  |  | (50 | ) |  |  | (87 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (58 | ) |  |  | (58 | )
Depreciation and amortization |  |  | 373 |  |  |  | 97 |  |  |  | — |  |  |  | 470 |  |  |  | 8 |  |  |  | 478 |
Segment income (loss) before income taxes |  |  | 280 |  |  |  | 2,813 |  |  |  | (81 | ) |  |  | 3,012 |  |  |  | (1,664 | ) |  |  | 1,348 |
Income tax (benefit) expense |  |  | (170 | ) |  |  | 2 |  |  |  | — |  |  |  | (168 | ) |  |  | 35 |  |  |  | (133 | )
Segment income (loss) |  |  | 450 |  |  |  | 2,811 |  |  |  | (81 | ) |  |  | 3,180 |  |  |  | (1,699 | ) |  |  | 1,481 |
Expenditures for segment assets |  |  | 95 |  |  |  | 24 |  |  |  | — |  |  |  | 119 |  |  |  | 3 |  |  |  | 122 | (2)
Segment Reporting for the Quarter Ended September 30, 2019
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 10,081 |  |  | $ | 12,454 |  |  |  | — |  |  | $ | 22,535 |  |  | $ | — |  |  | $ | 22,535 |
Intercompany revenues |  |  | 75 |  |  |  | 38 |  |  |  | — |  |  |  | 113 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 3,338 |  |  |  | 1,819 |  |  |  | — |  |  |  | 5,157 |  |  |  | — |  |  |  | 5,157 |
Research and development |  |  | 85 |  |  |  | — |  |  |  | 74 |  |  |  | 159 |  |  |  | 6 |  |  |  | 165 |
Interest income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 77 |  |  |  | 77 |
Interest expense |  |  | (19 | ) |  |  | (5 | ) |  |  | — |  |  |  | (24 | ) |  |  | (75 | ) |  |  | (99 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (69 | ) |  |  | (69 | )
Depreciation and amortization |  |  | 243 |  |  |  | 79 |  |  |  | — |  |  |  | 322 |  |  |  | 6 |  |  |  | 328 |
Segment income (loss) before income taxes |  |  | 2,244 |  |  |  | 1,193 |  |  |  | (74 | ) |  |  | 3,363 |  |  |  | (1,413 | ) |  |  | 1,950 |
Income tax expense |  |  | 55 |  |  |  | — |  |  |  | — |  |  |  | 55 |  |  |  | — |  |  |  | 55 |
Segment income (loss) |  |  | 2,189 |  |  |  | 1,193 |  |  |  | (74 | ) |  |  | 3,308 |  |  |  | (1,413 | ) |  |  | 1,895 |
Expenditures for segment assets |  |  | 470 |  |  |  | 31 |  |  |  | — |  |  |  | 501 |  |  |  | — |  |  |  | 501 | (3)
Segment Reporting for the Nine Months Ended September 30, 2020
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 24,469 |  |  | $ | 52,610 |  |  |  | — |  |  | $ | 77,079 |  |  | $ | — |  |  | $ | 77,079 |
Intercompany revenues |  |  | 879 |  |  |  | 19 |  |  |  | — |  |  |  | 898 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 5,533 |  |  |  | 7,167 |  |  |  | — |  |  |  | 12,700 |  |  |  | — |  |  |  | 12,700 |
Research and development |  |  | 194 |  |  |  | 119 |  |  |  | 221 |  |  |  | 534 |  |  |  | 64 |  |  |  | 598 |
Interest income |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 1 |  |  |  | 111 |  |  |  | 112 |
Interest expense |  |  | (80 | ) |  |  | (13 | ) |  |  | — |  |  |  | (93 | ) |  |  | (213 | ) |  |  | (306 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (187 | ) |  |  | (187 | )
Depreciation and amortization |  |  | 912 |  |  |  | 259 |  |  |  | — |  |  |  | 1,171 |  |  |  | 18 |  |  |  | 1,189 |
Segment income (loss) before income taxes |  |  | 2,577 |  |  |  | 5,162 |  |  |  | (221 | ) |  |  | 7,518 |  |  |  | (4,597 | ) |  |  | 2,921 |
Income tax (benefit) expense |  |  | (165 | ) |  |  | 2 |  |  |  | — |  |  |  | (163 | ) |  |  | 35 |  |  |  | (128 | )
Segment income (loss) |  |  | 2,742 |  |  |  | 5,160 |  |  |  | (221 | ) |  |  | 7,681 |  |  |  | (4,632 | ) |  |  | 3,049 |
Expenditures for segment assets |  |  | 1,095 |  |  |  | 385 |  |  |  | — |  |  |  | 1,480 |  |  |  | 8 |  |  |  | 1,488 | (2)
Segment Reporting for the Nine Months Ended September 30, 2019
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 30,079 |  |  | $ | 21,299 |  |  |  | — |  |  | $ | 51,378 |  |  | $ | — |  |  | $ | 51,378 |
Intercompany revenues |  |  | 83 |  |  |  | 101 |  |  |  | — |  |  |  | 184 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 8,921 |  |  |  | 2,008 |  |  |  | — |  |  |  | 10,929 |  |  |  | — |  |  |  | 10,929 |
Research and development |  |  | 367 |  |  |  | — |  |  |  | 228 |  |  |  | 595 |  |  |  | 20 |  |  |  | 615 |
Interest income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 265 |  |  |  | 265 |
Interest expense |  |  | (66 | ) |  |  | (18 | ) |  |  | — |  |  |  | (84 | ) |  |  | (209 | ) |  |  | (293 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (139 | ) |  |  | (139 | )
Depreciation and amortization |  |  | 713 |  |  |  | 236 |  |  |  | — |  |  |  | 949 |  |  |  | 19 |  |  |  | 968 |
Segment income (loss) before income taxes |  |  | 5,731 |  |  |  | 318 |  |  |  | (228 | ) |  |  | 5,821 |  |  |  | (4,003 | ) |  |  | 1,818 |
Income tax expense |  |  | 99 |  |  |  | — |  |  |  | — |  |  |  | 99 |  |  |  | — |  |  |  | 99 |
Segment income (loss) |  |  | 5,632 |  |  |  | 318 |  |  |  | (228 | ) |  |  | 5,722 |  |  |  | (4,003 | ) |  |  | 1,719 |
Expenditures for segment assets |  |  | 764 |  |  |  | 49 |  |  |  | — |  |  |  | 813 |  |  |  | — |  |  |  | 813 | (3)
(1) | Amounts reflect the activity for corporate headquarters not included in the segment information.
(2) | Net of financed amount of $751,000 and $883,000 for the three and nine months ended September 30, 2020, respectively.
(3) | Net of financed amount of $6,000 and $29,000 for the three and nine months ended September 30, 2019, respectively.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration